Business
Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
Orphan drug designation from Japan’s Ministry of Health, Labour and Welfare provides key regulatory benefits, including priority review and extended market exclusivity for potential treatments targeting diseases for which there is no sufficient alternativeA global Phase 2 PHocus study of mosliciguat in PH-ILD is currently ongoing and will be highlighted in a study-in-progress poster at the European Respiratory Society International Congress 2025 on September 28th WALTHAM, Mass., Sept. 04, 2025 (
About this update from Roivant Sciences Ltd.
[{"type":"image","alt":"Pulmovant, Inc.","displaySize":"","headline":null,"caption":"Pulmovant, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":108,"url":"https://media.zenfs.com/en/globenewswire.com/5c95ec62cb928b13aafcaaf1396a38dd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ZxCXGBa_9wg7zAAgfIM2Mg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5c95ec62cb928b13aafcaaf1396a38dd","width":300,"height":108}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Orphan drug designation from Japan’s Ministry of Health, Labour and Welfare provides key regulatory benefits, including priority review and extended market exclusivity for potential treatments targeting diseases for which there is no sufficient alternative","length":256,"tagName":"p"}]},{"val":[{"type":"text","content":"A global Phase 2 PHocus study of mosliciguat in PH-ILD is currently ongoing and will be highlighted in a study-in-progress poster at the European Respiratory Society International Congress 2025 on September 28th","length":211,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":467,"olType":false},{"type":"text","content":"WALTHAM, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Pulmovant, a clinical-stage biotechnology company committed to transforming the lives of patients with pulmonary diseases, and a Roivant (Nasdaq: ROIV) company, today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation (ODD) to mosliciguat, a novel, once-daily, inhaled soluble guanylate cyclase (sGC) activator, currently being studied for the treatment of Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD), which is a progressive and life-threatening condition with significant unmet medical need.","length":627,"tagName":"p"},{"type":"text","content":"“Obtaining orphan drug designation for mosliciguat in Japan validates the significant unmet need that exists for people living with PH-ILD, a progressive and life-threatening cardiopulmonary condition with poor prognosis and limited or no treatment options,” said Drew Fromkin, Chief Executive Officer of Pulmovant. “We appreciate the MHLW’s recognition of this challenge for PH-ILD patients and look forward to continued collaboration with Japanese regulators as we advance mo...